Sterling Pharma Solutions is a global CDMO specialising in complex API development, manufacturing, and bioconjugation services.

With over 50 years of expertise, Sterling Pharma Solutions delivers comprehensive contract development and manufacturing services for pharmaceutical and biotech clients worldwide. Headquartered in the UK, the company operates facilities across the UK, US, and Ireland, offering end-to-end support for small molecules, peptides, and antibody-drug conjugates (ADCs). Their innovative technologies, regulatory expertise, and commitment to sustainability drive efficient drug development and manufacturing, ensuring clients receive tailored, high-quality solutions at every lifecycle stage.

Key Products and Services

• Small Molecules: API development, hazardous chemistry, and cGMP manufacturing.
• Peptides: Long-chain peptide manufacturing, purification, and analysis.
• ADCs: Bioconjugation, analytical services, and clinical manufacturing.
• Specialised Technologies: High-potency APIs, flow chemistry, biocatalysis, and controlled substances.
• Lifecycle Services: From drug discovery to commercial launch.

Sterling Pharma Solutions prioritises technical excellence, customer collaboration, and sustainability. By integrating innovative technologies and scientific expertise, they empower pharmaceutical advancements while maintaining the highest quality standards and environmental stewardship. Their global reach and diverse capabilities ensure they remain a trusted partner in the pharmaceutical industry.